Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 in Neoadjuvant HER2+/HR+ Breast Cancer (ADAPT)
NCT01745965Phase 2Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Nov 2012
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Westdeutsche Studiengruppe. Started Nov 2012; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01745965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01745965.